相关实验视频

Updated: May 22, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

基于生物流体的阿尔茨海默氏症疾病的分期

Juan Lantero-Rodriguez¹, Laia Montoliu-Gaya², Nicholas J Ashton^2,3,4,5

¹Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. juan.rodriguez.2@gu.se.

Acta neuropathologica

|March 17, 2025

概括

像p-tau217,p-tau205和NTA-tau这样的液体生物标志物在脑脊液和血中显示出阿尔茨海默病 (AD) 病理阶段的前景. 这种生物流体分期与潜在的阿尔茨海默病特征很好地一致,有助于评估疾病的严重程度.

科学领域:

神经学神经学
生物标志物研究生物标志物研究
阿尔茨海默氏症疾病的诊断方法

背景情况:

使用液体生物标志物在体内确定阿尔茨海默病 (AD) 阶段的概念系统正在出现.
评估流体生物标志物的临床和生物相关性对于AD分期至关重要.

研究的目的:

探索p-tau217,p-tau205和NTA-tau对于基于生物流体的AD病理阶段的潜力.
为了比较生物流体分期与tau-PET索引的潜在病理.
为了评估脑脊液 (CSF) 和基于血的分期之间的一致性.

主要方法:

从TRIAD队列中抽取的CSF和血样本中分析p-tau217,p-tau205和NTA-tau.
生物流体分期与tau-PET成像的比较.
评估CSF和血分期之间的一致性.

主要成果:

在生物流体分期和潜在的AD病理 (最小的,早期到中间的,先进的tau结沉积) 之间观察到良好的一致性.
不一致的病例为4.6% (CSF) 和13.3% (血).
在61.7%的病例中,CSF和血分期相匹配;32%的病例显示CSF的分期较高.

结论:

使用p-tau217,p-tau205和NTA-tau的AD生物流体分期显示了对AD特征和疾病严重程度的潜在洞察力.
需要进一步的研究来证明在研究环境中超越分子表征的适用性.

关键词:

这就是阿尔茨海默病的原因.在CSF的CSF中,血等离子体的使用方法进行分期,分期.塔乌·塔乌 (Tau Tau) 是一个在p-Tau的位置上.

更多相关视频

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...